Platelet activation in patients with atherosclerotic renal artery stenosis undergoing stent revascularization

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 9, 2011, Pages 2185-2191

  Haller, Steven ^a   Adlakha, Satjit ^a   Reed, Grant ^b   Brewster, Pamela ^a   Kennedy, David ^c   Burket, Mark W ^a   Colyer, William ^a   Yu, Haifeng ^a   Zhang, Dong ^a   Shapiro, Joseph I ^a   Cooper, Christopher J ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CD40 LIGAND; CLOPIDOGREL; PLACEBO;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EMBOLIC PROTECTION DEVICE; EMBOLISM; FEMALE; HUMAN; KIDNEY ARTERY EMBOLIZATION; KIDNEY ARTERY STENOSIS; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; STENT; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM;

ADULT; ANGIOPLASTY; ANTIBODIES, MONOCLONAL; ATHEROSCLEROSIS; CD40 LIGAND; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET ACTIVATION; RENAL ARTERY OBSTRUCTION; STENTS;

EID: 80052625934     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03140411     Document Type: Article

References (38)

1. Levin A, Linas S, Luft FC, Chapman AB, Textor S: Controversies in renal artery stenosis: A review by the American Society of Nephrology Advisory Group on Hypertension. Am J Nephrol 27: 212-220, 2007
2. Balk E, Raman G, Chung M, Ip S, Tatsioni A, Alonso A, Chew P, Gilbert SJ, Lau J: Effectiveness of management strate-gies for renal artery stenosis: A systematic review. Ann Intern Med 145: 901-912, 2006
3. Olin JW: Survival in atherosclerotic renal artery stenosis: Its all about renal function, or is it? Catheter Cardiovasc Interv 69: 1048-1049, 2007
4. Arthurs Z, Starnes B, Cuadrado D, Sohn V, Cushner H, Andersen C: Renal artery stenting slows the rate of renal function decline. J Vasc Surg 45: 726-731, 2007
5. Safian RD, Textor SC: Renal-artery stenosis. N Engl J Med 344: 431-442, 2001
6. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM, Jr., White CJ, White J, White RA, Antman EM, Smith SC, Jr., Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B: ACC/ AHA 2005 Practice Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113: e463-e654, 2006
7. Cooper CJ, Murphy TP, Matsumoto A, Steffes M, Cohen DJ, Jaff M, Kuntz R, Jamerson K, Reid D, Rosenfield K, Rundback J, D'Agostino R, Henrich W, Dworkin L: Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: Rationale and design of the CORAL trial. Am Heart J 152: 59-66, 2006
8. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ: CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 92: 1041-1048, 2003
9. Chakrabarti S, Varghese S, Vitseva O, Tanriverdi K, Freedman JE: CD40 ligand influences platelet release of reactive oxygen intermediates. Arterioscler Thromb Vasc Biol 25: 2428-2434, 2005
10. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA: CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391: 591-594, 1998
11. Freedman JE: CD40-CD40L and platelet function: beyond hemostasis. Circ Res 92: 944-946, 2003
12. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD: CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 8: 247-252, 2002
13. Mason PJ, Chakrabarti S, Albers AA, Rex S, Vitseva O, Varghese S, Freedman JE: Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol 96: 1365-1369, 2005
14. Santilli F, Davi G, Consoli A, Cipollone F, Mezzetti A, Falco A, Taraborelli T, Devangelio E, Ciabattoni G, Basili S, Patrono C: Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 47: 391-397, 2006
15. Pontrelli P, Ursi M, Ranieri E, Capobianco C, Schena FP, Gesualdo L, Grandaliano G: CD40L proinflammatory and profibrotic effects on proximal tubular epithelial cells: Role of NF-kappaB and lyn. J Am Soc Nephrol 17: 627-636, 2006
16. Nannizzi-Alaimo L, Rubenstein MH, Alves VL, Leong GY, Phillips DR, Gold HK: Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation 105: 2849-2854, 2002
17. Kritharides L, Lau GT, Freedman B: Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348: 2575-2577, 2003
18. Burdon KP, Langefeld CD, Beck SR, Wagenknecht LE, Carr JJ, Rich SS, Freedman BI, Herrington D, Bowden DW: Variants of the CD40 gene but not of the CD40L gene are associated with coronary artery calcification in the Diabetes Heart Study (DHS). Am Heart J 151: 706-711, 2006
19. Welt FG, Rogers SD, Zhang X, Ehlers R, Chen Z, Nannizzi-Alaimo L, Phillips DR, Simon DI: GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention. Catheter Cardiovasc Interv 61: 185-189, 2004
20. Nannizzi-Alaimo L, Alves VL, Phillips DR: Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 107: 1123-1128, 2003
21. Cooper CJ, Haller ST, Colyer W, Steffes M, Burket MW, Thomas WJ, Safian R, Reddy B, Brewster P, Ankenbrandt MA, Virmani R, Dippel E, Rocha-Singh K, Murphy TP, Kennedy DJ, Shapiro JI, D'Agostino RD, Pencina MJ, Khuder S: Embolic protection and platelet inhibition during renal artery stenting. Circulation 117: 2752-2760, 2008
22. Burches B, Karnicki K, Wysokinski W, McBane RD, 2nd: Immunohistochemistry of thrombi following iliac venous stenting: a novel model of venous thrombosis. Thromb Haemost 96: 618-622. 2006
23. Stevens LA, Coresh J, Greene T, Levey AS: Assessing kidney Function-measured and estimated glomerular filtration rate. N Engl J Med 354: 2473-2483, 2006
24. Anand SX, Kim MC, Kamran M, Sharma SK, Kini AS, Fareed J, Hoppensteadt DA, Carbon F, Cavusoglu E, Varon D, Viles-Gonzalez JF, Badimon JJ, Marmur JD: Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol 100: 417-424, 2007
25. Garg R, Uretsky BF, Lev EI: Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv 70: 388-406, 2007
26. Santilli F, Basili S, Ferroni P, Davi G: CD40/CD40L system and vascular disease. Intern Emerg Med 2: 256-268, 2007
27. Turker S, Guneri S, Akdeniz B, Ozcan MA, Baris N, Badak O, Kirimli O, Yuksel F: Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease. Am J Cardiol 97: 198-202, 2006
28. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C: The CD40/CD40 ligand system: Linking inflammation with atherothrombosis. J Am Coll Cardiol 54: 669-677, 2009
29. Furman MI, Krueger LA, Linden MD, Fox ML, Ball SP, Barnard MR, Frelinger AL, 3rd, Michelson AD: GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost 3: 312-320, 2005
30. Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P, Bosa-Ojeda F, Samimi-Fard S, Marrero-Rodriguez F, Kaski JC: Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention-effects on soluble CD40 ligand concentrations. Atherosclerosis 206: 523-527, 2009
31. Starke A, Wuthrich RP, Waeckerle-Men Y: TGF-beta treatment modulates PD-L1 and CD40 expression in proximal renal tubular epithelial cells and enhances CD8 cytotoxic T-cell responses. Nephron Exp Nephrol 107: e22-29, 2007
32. Li H, Nord EP: IL-8 amplifies CD40/CD154-mediated ICAM-1 production via the CXCR-1 receptor and p38-MAPK pathway in human renal proximal tubule cells. Am J Physiol Renal Physiol 296: F438-F445, 2009
33. Kairaitis L, Wang Y, Zheng L, Tay YC, Harris DC: Blockade of CD40-CD40 ligand protects against renal injury in chronic proteinuric renal disease. Kidney Int 64: 1265-1272, 2003
34. Nguyen TA, Lordkipanidze M, Diodati JG, Palisaitis DA, Schampaert E, Turgeon J, Pharand C: Week-long high-maintenance dose clopidogrel regimen achieves better platelet aggregation inhibition than a standard loading dose before per-cutaneous coronary intervention: results of a double-blind, randomized clinical trial. J Interv Cardiol 22: 368-377, 2009
35. Fefer P, Hod H, Hammerman H, Segev A, Beinart R, Boyko V, Behar S, Matetzky S: Usefulness of pretreatment with high-dose clopidogrel in patients undergoing primary angioplasty for ST-elevation myocardial infarction. Am J Cardiol 104: 514-518, 2009
36. Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML: The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: The PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv 1: 612-619, 2008
37. Azar RR, Kassab R, Zoghbi A, Aboujaoude S, El-Osta H, Ghorra P, Germanos M, Salame E: Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 151: 521.e1-521.e4. 2006
38. Saw J, Madsen EH, Chan S, Maurer-Spurej E: The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. J Am Coll Cardiol 52: 1826-1833, 2008